On the other hand, Abdullah et al. [126] showed that the flotillin-1 level in serum and cerebrospinal fluid is significantly decreased in patients with Alzheimer’s disease as a result of diminished exosome release, and therefore, flotillin-1 can be used as a blood marker for the differential diagnosis of the disease from other cognitive impairments. This evidence concerns the gene FLOT1 and Alzheimer disease.